2024 European Society of Cardiology Guidelines
New ESC guidelines recommend renal denervation. Class IIb.1
The future of hypertension care is now
ESC guidelines recommend RDN for uncontrolled hypertension patients.
Elevate hypertension care options as you know them. ESC recommends RDN as a safe and effective complementary hypertension treatment option for your patients.1
- In patients with uncontrolled and resistant hypertension
- Treated with three or fewer antihypertensive drugs, including diuretic
Symplicity™ blood pressure procedure
> 9 mmHg
in OSBP in patients off
and on medications2,3
Over 25,000 real-world RDN patient and counting, Medtronic Symplicity™ blood pressure procedure is proven to deliver clinically significant, safe, and sustained BP reductions in multiple clinical trials.2–7
A third pillar of hypertension care.
Lifestyle
modification
Medication
management
Renal
denervation
Let’s connect!
Please fill the form to receive more information about
our Renal Denervation System.
Disclaimer: The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). For any further information, contact your local Medtronic representative.
1. McEvoy JW. et al, European Heart Journal, ehae178, https://doi.org/10.1093/eurheartj/ehae178.
2. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
3. Kandzari DE, Townsend RR, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
4. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.
5. Mahfoud F, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. Presented at EuroPCR 2023, Paris, France.
6. Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: Subgroup analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–1770. doi: 10.1161/HYPERTENSIONAHA.123.21283.
7. Medtronic data on file. RDN catheter historical data, June 2023. Data includes both Symplicity Flex™ and Symplicity Spyral™.